Prestige Biologics Doubles Revenue but Net Loss Widens to KRW 51.2 Billion; Biosecurity Law Could Provide Relief Amid Liquidity Crisis

Prestige Biologics more than doubled revenue in fiscal 2026 (July 2025 to June 2026) from the previous year, but its net loss widened as research and development expenses surged and cost pressures mounted. With current liabilities exceeding current assets by more than KRW 100 billion and uncertainty raised over the company’s ability to continue as a going concern, the global supply chain reorganization driven by the U.S. Biosecurity Act has emerged as a factor that could determine its future.

Why the loss widened despite surging revenue

According to the business report submitted to the Financial Supervisory Service’s Electronic Disclosure System on the 18th, Prestige Biologics’ separate-basis revenue for its 12th fiscal year was KRW 26.66514 billion, up 112.8% from KRW 12.53327 billion in the previous period. In particular, revenue in the fourth quarter of fiscal 2026 (April to June) reached KRW 11.47 billion, surpassing KRW 10 billion in quarterly revenue for the first time since the company’s listing. By revenue category, product revenue from contract manufacturing of active pharmaceutical ingredients and finished drugs rose 38.4% to KRW 14.46605 billion, while other revenue, including process development and technology transfers, surged 487.1% to KRW 12.19910 billion.

Despite the top-line growth, profitability deteriorated. Net loss for the period was KRW 51.220 billion, up 86.5% from KRW 27.46949 billion in the previous period, while operating loss also increased to KRW 49.302 billion from KRW 33.68164 billion. The company identified the sharp increase in research and development expenses as the main reason for the wider loss. R&D expenses in the 12th fiscal year rose to KRW 20.22015 billion, approximately 7.8 times the KRW 2.58836 billion recorded in the previous period. The increase resulted from concentrated investment in technology, including the establishment of Korea’s first full single-use system and the acquisition of a patent for artificial intelligence-integrated cell culture optimization.

Debt-to-equity ratio reaches 195% as going-concern uncertainty flagged

The deterioration in the financial structure is even more serious. Total liabilities at the end of the 12th fiscal year were KRW 176.10135 billion, up 30.4% from KRW 135.08296 billion at the end of the previous period, while total equity fell 33.1% to KRW 90.45548 billion. The debt-to-equity ratio soared from 99.91% to 194.68%. Current liabilities of KRW 152.4 billion exceeded current assets of KRW 44.9 billion by approximately KRW 107.59744 billion, indicating severe funding pressure.

The external auditor noted in its audit opinion on the business report that the substantial excess of current liabilities over current assets and the large operating loss indicated the existence of material uncertainty that could raise significant doubt about the company’s ability to continue as a going concern. However, the auditor issued an unqualified opinion on the financial statements themselves. After the share price also fell to the KRW 1,600 range, its 52-week low, the company’s board decided on Sept. 11 to conduct a one-for-five reverse stock split. The total number of issued shares will decrease by 80%, from approximately 77.75 million to 15.55 million. The new shares are scheduled to be listed on Nov. 24.

Opportunity created by the China-exit supply chain reorganization

Prestige Biologics is a biopharmaceutical contract development and manufacturing organization in Osong, Cheongju, North Chungcheong Province, with total production capacity of 154,000 liters. The number of new contracts in the 12th fiscal year rose to 57 from 41 in the previous period. During the fiscal year, the company also expanded its order backlog by signing six large new contracts worth approximately KRW 41.2 billion in total with global customers and others. Management said global pharmaceutical companies that had relied on China are seeking new production bases in the wake of the U.S. Biosecurity Act and that inquiries about new contracts have been flooding in. The company said its early adoption of single-use technology similar to that of China’s WuXi Biologics is strengthening its competitiveness as an alternative production base.

However, the company must first overcome its immediate financial crisis to turn these opportunities into reality. Its survival depends on how quickly it can convert its large order volume into actual revenue and operating cash flow, as well as whether it can secure additional financing to address its liquidity shortfall in the KRW 100 billion range. The company has the potential to become a top-tier global contract development and manufacturing organization, supported by a full value-chain strategy spanning early development through large-scale commercial production and flexible single-use processes. But if it fails to clear its financial hurdle, that potential could also lose its luster.